InnoCan Pharma Soars with Strong Q2 2024 Financials
Company Announcements

InnoCan Pharma Soars with Strong Q2 2024 Financials

Story Highlights

InnoCan Pharma (TSE:INNO) has released an update.

InnoCan Pharma has reported a significant growth in their second-quarter 2024 revenues, with a 177% increase to $8.6 million, and a substantial improvement in profitability, including a net profit of $0.95 million. This financial growth is attributed to the strong sales of its subsidiary BI Sky Global Ltd. and advancements in its innovative drug delivery technologies.

For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskInnocan Pharma’s LPT-CBD Eases Dog Arthritis Pain
TipRanks Canadian Auto-Generated NewsdeskInnoCan Pharma’s Advisor Among Top Cited Scientists
TipRanks Canadian Auto-Generated NewsdeskInnocan Pharma’s LPT-CBD Nears FDA Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App